Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials

Open access

Abstract

BACKGROUND: Schizophrenia and bipolar depression trials suggest that quetiapine may have an antidepressant effect. OBJECTIVES: This meta-analysis aimed to determine the efficacy, acceptability and tolerability of quetiapine treatment for major depressive disorder (MDD). Only the randomized controlled trials (RCTs) comparison between quetiapine and placebo were included. The authors searched such clinical trials carried out between 1991 and February 2012. DATA SOURCES: MEDLINE, EMBASE, CINHL, PsycINFO and Cochrane Controlled Trials Register were searched in February 2012. Study populations comprised adults with MDD or major depression. STUDY ELIGIBLE CRITERIA, PARTICIPANTS AND INTERVENTIONS: Eligible studies were randomized, placebo-controlled trials of quetiapine monotherapy carried out in adults with MDD and presenting endpoint outcomes relevant to: i) depression severity, ii) response rate, iii) overall discontinuation rate, or iv) discontinuation rate due to adverse events. No language restriction was applied. STUDY APPRAISAL AND SYNTHESIS METHODS: All abstracts identified by the electronic searches were examined. The full reports of relevant studies were assessed, and the data of interest were extracted. Based on the Cochrane methods of bias assessment, risks of bias were determined. The studies with two risks or less were included. The efficacy outcomes were the mean change scores of depression rating scales, the overall response rate, and the overall remission rates. The overall discontinuation rate was considered as a measure of acceptability. The discontinuation rate due to adverse events was a measure of tolerability. Relative risks (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs) were computed by using a random effect model. RESULTS: A total of 1,497 participants in three RCTs were included. All trials examined the quetiapine extended-release (XR). The pooled mean change scores of the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating Scale (HAM-D) of the quetiapine-treated group were higher than those of the placebo-treated group with the WMDs (95%CI) of -3.37 (-3.95, -2.79) and -2.46 (-3.47, -1.45), respectively. All studies defined the response and remission as ≥ 50% reduction of the MADRS total score and the MADRS total score of ≤8 at endpoint, respectively. The overall response and remission rates were significantly greater in the quetiapine-treated group with RRs (95%CIs) of 1.44 (1.26, 1.64) and 1.37 (1.12, 1.68), respectively. The pooled discontinuation rate was not significantly different between groups with an RR (95%CI) of 1.16 (0.97, 1.39). The pooled discontinuation rate due to adverse event was greater in the quetiapine group with an RR (95%CI) of 2.90 (1.87, 4.48). With respect to sleep time, the pooled mean change Pittsburgh Sleep Quality Index (PSQI) scores of the quetiapine-treated group was also significantly higher than that of the placebo-treated group [WMD (95%CI) of -1.21 (-1.81, -0.61)]. LIMITATIONS: Variety of quetiapine XR doses and the small number of RCTs were key limitations of this meta-analysis. CONCLUSIONS: Based on the limited evidence obtained from three RCTs, quetiapine XR is effective for adult patients with MDD. The high dropout rate due to adverse events suggests that some MDD patients may not be able to tolerate quetiapine XR. Due to the balance of its efficacy benefit and risk of side effects, as the overall discontinuation rate shown, the acceptability of this agent is not more than placebo. These results should be viewed as the very preliminary one. Further studies in this area are warranted. IMPLICATION OF KEY FINDINGS: Quetiapine may be an alternative antidepressant. However, both risk and benefit of this agent should be taken into account for an individual patient with MDD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-244x-12-160

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram of study * http://www.astrazenecaclinicaltrials.com/drug-products/seroquel/.
Figure 1 Flow diagram of study * http://www.astrazenecaclinicaltrials.com/drug-products/seroquel/.CC BY · PubMed Central
Figure 2 Comparison of relative risk (95% confidence interval) for clinical response rates in patients with MDD: quetiapine vs. placebo.
Figure 2 Comparison of relative risk (95% confidence interval) for clinical response rates in patients with MDD: quetiapine vs. placebo.CC BY · PubMed Central
Figure 3 Comparison of relative risk (95% confidence interval) for clinical remission rates in patients with MDD: quetiapine vs. placebo.
Figure 3 Comparison of relative risk (95% confidence interval) for clinical remission rates in patients with MDD: quetiapine vs. placebo.CC BY · PubMed Central
Figure 4 Comparison the mean changes from baseline of MADRS (95% confidence interval) in patients with MDD: quetiapine vs. placebo.
Figure 4 Comparison the mean changes from baseline of MADRS (95% confidence interval) in patients with MDD: quetiapine vs. placebo.CC BY · PubMed Central
Figure 5 Comparison the mean changes from baseline of HAM-D (95% confidence interval) in patients with MDD: quetiapine vs. placebo.
Figure 5 Comparison the mean changes from baseline of HAM-D (95% confidence interval) in patients with MDD: quetiapine vs. placebo.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Papakostas GI: Tolerability of modern antidepressants. J Clin Psychiatry. 2008, 69 (E1): 8-13.

Cited by

See all 51

Metadata

Authors
Maneeton, N., Maneeton, B., Srisurapanont, M., & Martin, S. D.
Affiliations
Chiang Mai University (TH)
Corresponding author
Maneeton, Benchalak
Venue
BMC Psychiatry
Published
2012-09-27
Volume
12
Issue
1
Pages
160-160
ISSN
1471-244X (ISSN-L)
OpenAlex
W2095811380
Cited by
51
References
53
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 6 · 2013: 5
FWCI
0.59
Type
journal article
Language
en
Open access
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Greater South Information System
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
quetiapine, major depressive disorder, antidepressant monotherapy, atypical antipsychotics, acute phase treatment, treatment response, remission, treatment discontinuation, adverse events, tolerability, sustained-release formulation, placebo comparison, risk of bias, depression rating scales, antidepressant efficacy, antidepressant tolerability, bipolar depression, atypical depression
MeSH terms
Quetiapine Fumarate, Acute Disease, Adolescent, Adult, Aged, Antidepressive Agents, Delayed-Action Preparations, Major Depressive Disorder, Dibenzothiazepines, Female, Humans, Male, Middle Aged, Placebos, Remission Induction, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. https://app.cochat.ai/papers/10.1186/1471-244x-12-160
The paper
Maneeton, N., Maneeton, B., Srisurapanont, M., & Martin, S. D. (2012). Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. https://doi.org/10.1186/1471-244x-12-160

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.